Literature DB >> 26355156

EBI3 Downregulation Contributes to Type I Collagen Overexpression in Scleroderma Skin.

Hideo Kudo1, Zhongzhi Wang1, Masatoshi Jinnin2, Wakana Nakayama1, Kuniko Inoue1, Noritoshi Honda1, Taiji Nakashima1, Ikko Kajihara1, Katsunari Makino1, Takamitsu Makino1, Satoshi Fukushima1, Hironobu Ihn1.   

Abstract

IL-12 family cytokines are implicated in the pathogenesis of various autoimmune diseases, but their role in the regulation of extracellular matrix expression and its contribution to the phenotype of systemic sclerosis (SSc) remain to be elucidated. Among the IL-12 family members, IL-35 decreases type I collagen expression in cultured dermal fibroblasts. IL-35 consists of p35 and EBI3 subunits, and EBI3 alone could downregulate the protein and mRNA expression of type I or type III collagen in the presence or absence of TGF-β costimulation. We found that collagen mRNA stability was reduced by EBI3 via the induction of miR-4500. The IL-35 levels in the sera or on the surface of T cells were not altered in SSc patients, while EBI3 expression was decreased in the keratinocytes of the epidermis and regulatory T cells of the dermis in SSc skin compared with normal skin, which may induce collagen synthesis in SSc dermal fibroblasts. We also found that gp130, the EBI3 receptor, was expressed in both normal and SSc fibroblasts. Moreover, we revealed that EBI3 supplementation by injection into the skin improves mice skin fibrosis. Decreased EBI3 in SSc skin may contribute to an increase in collagen accumulation and skin fibrosis. Clarifying the mechanism regulating the extracellular matrix expression by EBI3 in SSc skin may lead to better understanding of this disease and new therapeutic strategies using ointment or microinjection of the subunit.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26355156     DOI: 10.4049/jimmunol.1402362

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Higher levels of serum interleukin-35 are associated with the severity of pulmonary fibrosis and Th2 responses in patients with systemic sclerosis.

Authors:  Jie Tang; Ling Lei; Jie Pan; Cheng Zhao; Jing Wen
Journal:  Rheumatol Int       Date:  2018-05-30       Impact factor: 2.631

2.  [Expression of pituitary tumor-transforming gene-1 and its pathogenic role in systemic sclerosis].

Authors:  Anqiao Yang; Yan Huang; Yuting Zhang; Kai Yang; Jiucun Wang; Qingmei Liu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2020-11-30

Review 3.  IL-35: a new immunomodulator in autoimmune rheumatic diseases.

Authors:  Lazaros I Sakkas; Athanasios Mavropoulos; Carlo Perricone; Dimitrios P Bogdanos
Journal:  Immunol Res       Date:  2018-06       Impact factor: 4.505

Review 4.  Expanding Diversity in Molecular Structures and Functions of the IL-6/IL-12 Heterodimeric Cytokine Family.

Authors:  Hideaki Hasegawa; Izuru Mizoguchi; Yukino Chiba; Mio Ohashi; Mingli Xu; Takayuki Yoshimoto
Journal:  Front Immunol       Date:  2016-11-04       Impact factor: 7.561

Review 5.  Interleukin 39: a new member of interleukin 12 family.

Authors:  Zhiyu Lu; Keye Xu; Xiaoying Wang; Yan Li; Mingcai Li
Journal:  Cent Eur J Immunol       Date:  2020-07-27       Impact factor: 2.085

6.  Modulation by 17,20S(OH)2pD of Fibrosis-Related Mediators in Dermal Fibroblast Lines from Healthy Donors and from Patients with Systemic Sclerosis.

Authors:  Monica L Brown Lobbins; Andrzej T Slominski; Karen A Hasty; Sicheng Zhang; Duane D Miller; Wei Li; Tae-Kang Kim; Zorica Janjetovic; Robert C Tuckey; Imara-Safi O Scott; Linda K Myers; Arnold E Postlethwaite
Journal:  Int J Mol Sci       Date:  2021-12-29       Impact factor: 5.923

Review 7.  Interleukin-35 in autoimmune dermatoses: Current concepts.

Authors:  Yuming Xie; Huilin Zhang; Junke Huang; Qing Zhang
Journal:  Open Med (Wars)       Date:  2022-03-21

8.  Multifaceted Analysis of IL-23A- and/or EBI3-Including Cytokines Produced by Psoriatic Keratinocytes.

Authors:  Kota Tachibana; Nina Tang; Hitoshi Urakami; Ai Kajita; Mina Kobashi; Hayato Nomura; Minori Sasakura; Satoru Sugihara; Fan Jiang; Nahoko Tomonobu; Masakiyo Sakaguchi; Mamoru Ouchida; Shin Morizane
Journal:  Int J Mol Sci       Date:  2021-11-23       Impact factor: 5.923

Review 9.  A Chaperone-Like Role for EBI3 in Collaboration With Calnexin Under Inflammatory Conditions.

Authors:  Aruma Watanabe; Izuru Mizoguchi; Hideaki Hasegawa; Yasuhiro Katahira; Shinya Inoue; Eri Sakamoto; Yuma Furusaka; Ami Sekine; Satomi Miyakawa; Fumihiro Murakami; Mingli Xu; Toshihiko Yoneto; Takayuki Yoshimoto
Journal:  Front Immunol       Date:  2021-09-17       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.